Medical equipment company Smith & Nephew has agreed a $660 million deal to buy US biotech Osiris Therapeutics that expands its business into regenerative medicine.
Smith & Nephew has launched a handheld imaging device that instantly measures wound surface area, and showing the presence and distribution of potentially harmful bacteria.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio